Zymeworks PE Ratio 2016-2022 | ZYME
Current and historical p/e ratio for Zymeworks (ZYME) from 2016 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Zymeworks PE ratio as of March 24, 2023 is 4.63.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Zymeworks PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-03-24 |
8.20 |
|
0.00 |
| 2022-06-30 |
5.30 |
$-4.36 |
0.00 |
| 2022-03-31 |
6.55 |
$-4.70 |
0.00 |
| 2021-12-31 |
16.39 |
$-4.38 |
0.00 |
| 2021-09-30 |
29.04 |
$-4.17 |
0.00 |
| 2021-06-30 |
34.69 |
$-4.35 |
0.00 |
| 2021-03-31 |
31.58 |
$-3.81 |
0.00 |
| 2020-12-31 |
47.26 |
$-3.58 |
0.00 |
| 2020-09-30 |
46.58 |
$-4.50 |
0.00 |
| 2020-06-30 |
36.07 |
$-3.77 |
0.00 |
| 2020-03-31 |
35.47 |
$-3.89 |
0.00 |
| 2019-12-31 |
45.46 |
$-3.68 |
0.00 |
| 2019-09-30 |
24.80 |
$-1.73 |
0.00 |
| 2019-06-30 |
22.00 |
$-1.62 |
0.00 |
| 2019-03-31 |
16.18 |
$-0.95 |
0.00 |
| 2018-12-31 |
14.68 |
$-1.35 |
0.00 |
| 2018-09-30 |
15.70 |
$-0.36 |
0.00 |
| 2018-06-30 |
14.78 |
$-0.42 |
0.00 |
| 2018-03-31 |
12.02 |
$-0.83 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.525B |
$0.412B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
